Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction.
暂无分享,去创建一个
R. Califf | P. Armstrong | M. Krucoff | M. Simoons | G. Wagner | A. Langer | C. Wyatt | C. Green | A. Maas | K. Trollinger | J. Pope
[1] E. Ohman,et al. Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. , 2002, American heart journal.
[2] R. Califf,et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. , 2000, Journal of the American College of Cardiology.
[3] R. Califf,et al. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. , 1998, Journal of the American College of Cardiology.
[4] N. Fineberg,et al. Clinical utility of troponin T levels and echocardiography in the emergency department. , 1998, American heart journal.
[5] H. Arendrup,et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. , 1997, Circulation.
[6] R. Califf,et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. , 1997, Circulation.
[7] T. Böhm,et al. Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1997, European heart journal.
[8] European Cooperative Study Group,et al. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction , 1996, The Lancet.
[9] P. Armstrong,et al. Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1996, European heart journal.
[10] R. Califf,et al. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. , 1996, The American journal of cardiology.
[11] J. Deckers,et al. Estimated gain in life expectancy , 1996 .
[12] M L Simoons,et al. Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. , 1996, European heart journal.
[13] R. D. de Winter,et al. Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. , 1995, Circulation.
[14] K Wegscheider,et al. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. , 1995, Journal of the American College of Cardiology.
[15] F. Van de Werf,et al. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group. , 1995, Circulation.
[16] R. Califf,et al. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, Journal of the American College of Cardiology.
[17] R. Califf,et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. , 1995, Circulation.
[18] J Col,et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.
[19] K. Swedberg,et al. Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction. , 1995, European heart journal.
[20] R. Califf,et al. Intravenous Fluosol in the Treatment of Acute Myocardial Infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial , 1994, Circulation.
[21] J E Pope,et al. From signal/noise to information content/noise. Reconsidering the statistical analysis of continuous ST-segment data streams with gaps: potential optimization of application-specific information content using left, right, and interval censoring. , 1994, Journal of electrocardiology.
[22] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[23] M. Simoons,et al. Tailored Thrombolytic Therapy A Perspective , 1993, Circulation.
[24] R. Califf,et al. Continuous 12‐Lead ST‐Segment Recovery Analysis in the TAMI 7 Study Performance of a Noninvasive Method for Real‐Time Detection of Failed Myocardial Reperfusion Detection of Failed Myocardial Reperfusion , 1993, Circulation.
[25] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[26] H. Hod,et al. Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction. , 1990, British heart journal.
[27] M. Krucoff,et al. The portable programmable microprocessor-driven real-time 12-lead electrocardiographic monitor: a preliminary report of a new device for the noninvasive detection of successful reperfusion or silent coronary reocclusion. , 1990, The American journal of cardiology.
[28] P. Serruys,et al. Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase? , 1986, Circulation.